Finasteride (3.25%) Formulation



Version **Revision Date:** SDS Number: Date of last issue: 23.03.2020 10.10.2020 2160731-00008 Date of first issue: 09.11.2017 1.7

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Finasteride (3.25%) Formulation

Manufacturer or supplier's details

: Organon & Co. Company

Address 30 Hudson Street, 33nd floor

Jersey City, New Jersey, U.S.A 07302

Telephone 551-430-6000

Emergency telephone number : 215-631-6999

E-mail address EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Reproductive toxicity : Category 1B

Specific target organ toxicity - : Category 2 (Testis)

repeated exposure (Oral)

GHS label elements

Hazard pictograms

Signal word

Hazard statements H360D May damage the unborn child.

H373 May cause damage to organs (Testis) through prolonged

or repeated exposure if swallowed.

Precautionary statements Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray. P281 Use personal protective equipment as required.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:



Finasteride (3.25%) Formulation



Version **Revision Date:** SDS Number: Date of last issue: 23.03.2020 10.10.2020 2160731-00008 Date of first issue: 09.11.2017 1.7

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	< 10
Starch	9005-25-8	< 10
Finasteride	98319-26-7	>= 1 -< 10

SECTION 4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

delayed

May damage the unborn child.

May cause damage to organs through prolonged or repeated exposure if swallowed.

First Aid responders should pay attention to self-protection, Protection of first-aiders

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing None known.

Finasteride (3.25%) Formulation



Version **Revision Date:** SDS Number: Date of last issue: 23.03.2020 10.10.2020 2160731-00008 Date of first issue: 09.11.2017 1.7

media

Specific hazards during fire-

Hazardous combustion prod-

ucts

Specific extinguishing meth-

ods

Exposure to combustion products may be a hazard to health.

Carbon oxides Metal oxides

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

Special protective equipment

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Hazchem Code 2Z

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Avoid release to the environment. **Environmental precautions**

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for

containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling Do not get on skin or clothing.

Do not breathe dust, fume, gas, mist, vapours or spray.

Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the



Finasteride (3.25%) Formulation



Version Revision Date: SDS Number: Date of last issue: 23.03.2020 1.7 10.10.2020 2160731-00008 Date of first issue: 09.11.2017

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of	Control parame- ters / Permissible	Basis	
		exposure)	concentration		
Cellulose	9004-34-6	TWA	10 mg/m3	AU OEL	
	Further information: This value is for inhalable dust containing no				
	asbestos and < 1% crystalline silica				
		TWA	10 mg/m3	ACGIH	
Starch	9005-25-8	TWA	10 mg/m3	AU OEL	
	Further information: This value is for inhalable dust containing no				
	asbestos and < 1% crystalline silica				
		TWA	10 mg/m3	ACGIH	
Finasteride	98319-26-7	TWA	0.5 µg/m3 (OEB	Internal	
			5)		
		Wipe limit	5 μg/100 cm ²	Internal	

Engineering measures

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to pre-

vent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems

are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the


workplace.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.





Version Revision Date: SDS Number: Date of last issue: 23.03.2020 1.7 10.10.2020 2160731-00008 Date of first issue: 09.11.2017

Filter type : Particulates type Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : solid

Colour : blue

Odour : odourless

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available



Finasteride (3.25%) Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 1.7
 10.10.2020
 2160731-00008
 Date of first issue: 09.11.2017

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Skin contact Ingestion

Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Components:

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist



Finasteride (3.25%) Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 1.7
 10.10.2020
 2160731-00008
 Date of first issue: 09.11.2017

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Finasteride:

Acute oral toxicity : LD50 (Rat): 373 - 828 mg/kg

LD50 (Mouse): 486 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Finasteride:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Starch:

Species : Rabbit

Result : No eye irritation

Finasteride:

Species : Rabbit

Remarks : slight irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Starch:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Finasteride (3.25%) Formulation



Version 1.7

Revision Date: 10.10.2020

SDS Number: 2160731-00008

Date of last issue: 23.03.2020 Date of first issue: 09.11.2017

Chronic toxicity

Germ cell mutagenicity

Not classified based on available information.

Components:

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Finasteride:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

Result: positive

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Alkaline elution assay

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Application Route: Oral

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative



Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 23.03.2020 1.7 10.10.2020 2160731-00008 Date of first issue: 09.11.2017

Finasteride:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years

160 mg/kg body weight

Result : negative Target Organs : Testes

Remarks : Benign tumor(s)

Species : Mouse
Application Route : Ingestion
Exposure time : 19 month(s)
Result : negative
Target Organs : Testes

Remarks : Benign tumor(s)

Reproductive toxicity

May damage the unborn child.

Components:

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Finasteride:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rabbit Application Route: Oral

Fertility: NOAEL: 80 mg/kg body weight

Result: No effects on fertility

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Fertility: LOAEL: 80 mg/kg body weight

Result: positive

Remarks: There is no evidence that these findings are rele-

vant to humans.

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Developmental Toxicity: LOAEL: 0.003 mg/kg body weight

Result: Teratogenic effects, Embryotoxic effects.

Test Type: Embryo-foetal development



Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 23.03.2020 1.7 10.10.2020 2160731-00008 Date of first issue: 09.11.2017

Species: Monkey

Application Route: Ingestion

Developmental Toxicity: LOAEL: 2 mg/kg body weight

Result: Teratogenic effects

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Testis) through prolonged or repeated exposure if swallowed.

Components:

Finasteride:

Exposure routes : Ingestion Target Organs : Testis

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg

Application Route : Ingestion Exposure time : 90 Days

Starch:

Species : Rat

NOAEL : >= 2,000 mg/kg
Application Route : Skin contact
Exposure time : 28 Days

Method : OECD Test Guideline 410

Finasteride:

Species : Rat

NOAEL : 20 mg/kg

LOAEL : 40 mg/kg

Application Route : Oral

Exposure time : 1 yr

Target Organs : Testis

Species : Dog
NOAEL : 45 mg/kg
Application Route : Oral
Exposure time : 1 yr
Target Organs : Testis

Finasteride (3.25%) Formulation



Version Revision Date: SDS Number: Date of last issue: 23.03.2020 1.7 10.10.2020 2160731-00008 Date of first issue: 09.11.2017

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Finasteride:

Ingestion : Symptoms: breast tenderness, breast enlargement, impo-

tence, lip swelling, skin rash

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Finasteride:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 20.4 mg/l

Exposure time: 96 h Method: FDA 4.11

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 17.8 mg/l

Exposure time: 48 h Method: FDA 4.08

Toxicity to algae/aquatic

plants

NOEC (Pseudokirchneriella subcapitata (green algae)): 49

mg/l

Exposure time: 14 h Method: FDA 4.01

Toxicity to fish (Chronic tox-

icity)

NOEC (Oryzias latipes (Orange-red killifish)): 0.05 mg/l

Exposure time: 105 d

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.12 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Finasteride:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 0 %



Date of first issue: 09.11.2017

Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 23.03.2020

2160731-00008

Exposure time: 7 d Method: FDA 3.11

Stability in water : Hydrolysis: 0 %(5 d)

Method: FDA 3.09

Bioaccumulative potential

10.10.2020

Components:

1.7

Finasteride:

Partition coefficient: n-

octanol/water

log Pow: 3.57

Mobility in soil
No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Finasteride)

Class : 9
Packing group : III
Labels : 9

IATA-DGR

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

(Finasteride)

956

956

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo

aircraft)

Packing instruction (passen:

ger aircraft)

Environmentally hazardous : yes

IMDG-Code

12 / 15



ORGANON

Finasteride (3.25%) Formulation

Version Revision Date: SDS Number: Date of last issue: 23.03.2020 1.7 10.10.2020 2160731-00008 Date of first issue: 09.11.2017

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Finasteride)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

ADG

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Finasteride)

Class : 9
Packing group : III
Labels : 9
Hazchem Code : 2Z

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Prohibition/Licensing Requirements : There is no applicable prohibition,

authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regula-

tions.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Finasteride (3.25%) Formulation



Version Revision Date: SDS Number: Date of last issue: 23.03.2020 1.7 10.10.2020 2160731-00008 Date of first issue: 09.11.2017

SECTION 16. OTHER INFORMATION

Further information

Revision Date : 10.10.2020

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Sheet

cy, http://echa.europa.eu/

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

AU OEL : Australia. Workplace Exposure Standards for Airborne Con-

taminants.

ACGIH / TWA : 8-hour, time-weighted average

AU OEL / TWA : Exposure standard - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate: NOM - Official Mexican Norm: NTP - National Toxicology Program: NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS mate-



Finasteride (3.25%) Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 1.7
 10.10.2020
 2160731-00008
 Date of first issue: 09.11.2017

rial is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN